Year: 2007
Type: review
Abstract: Colorectal cancer remains the second leading cause of cancer-related mortality in the United States. Although surgical resection is still the primary treatment for colorectal cancer, in recent years, there has been a remarkable progress in the development of new therapies to treat colorectal cancer. Response rates have increased substantially and new immunotherapeutic approaches are shedding new light in the battle against the disease. This review will focus on the current immunotherapeutic approaches being developed and will discuss clinical data for some of these new treatments.
Source: Cancer Biology & Therapy
DOI: 10.4161/cbt.6.1.3672
Authors: Rafael Cubas, Min Li, Changyi Chen, Qizhi Yao
Institution: Baylor College of Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1821703018, HIV PROTEASE INHIBITORS EFFECT--NENDOTHELIAL DYSFUNCTION, TARGETED MUTAGENESIS OF NEUROENDOCRINE REGULATORY GENES, Effects of HIV Protease Inhibitors of Endothelial Barrie, Tissue engineering of small diameter vascular graft, Influenza HA in SHIV VLPS for mucosal vaccination, Ginkgo Biloba Enhances Therapeutic HIV Vaccination, G6170213943, G6217743226, G640625107, G675304304
OpenAlex ID: W2090959494